[Congressional Bills 110th Congress]
[From the U.S. Government Publishing Office]
[H.R. 2223 Introduced in House (IH)]







110th CONGRESS
  1st Session
                                H. R. 2223

 To direct the Director of the Office of National Drug Control Policy, 
 in consultation with the Attorney General and the Secretary of Health 
 and Human Services, to conduct a study on prescription drug take-back 
                   programs, and for other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                              May 8, 2007

   Mr. Porter (for himself and Mr. Heller of Nevada) introduced the 
   following bill; which was referred to the Committee on Energy and 
                                Commerce

_______________________________________________________________________

                                 A BILL


 
 To direct the Director of the Office of National Drug Control Policy, 
 in consultation with the Attorney General and the Secretary of Health 
 and Human Services, to conduct a study on prescription drug take-back 
                   programs, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. PRESCRIPTION DRUG TAKE-BACK PROGRAMS STUDIES.

    (a) Study Conducted by Director of the Office of National Drug 
Control Policy.--
            (1) Study required.--The Director of the Office of National 
        Drug Control Policy, in consultation with the Attorney General 
        and the Secretary of Health and Human Services, shall conduct a 
        study on prescription drug disposal programs (in this Act 
        referred to as ``take-back programs'') in which individuals 
        return unused prescription drugs to pharmacies or other 
        locations.
            (2) Focus of study.--The study required under paragraph (1) 
        shall focus on the following:
                    (A) The methodology, processes, technology, and 
                best practices with respect to such take-back programs.
                    (B) The affects of such take-back programs on 
                pharmacies.
                    (C) Training and infrastructure needed to ensure 
                the success of such take-back programs.
                    (D) Identifying the number of individuals that use 
                current take-back programs.
                    (E) Identifying any changes to existing laws that 
                would allow for full, nationwide implementation of such 
                take-back programs.
                    (F) Identifying the costs to pharmacies of such 
                take-back programs.
                    (G) Identifying methods by which prescription drugs 
                can be tracked after they are surrendered at pharmacies 
                and other locations, and ways in which the Federal 
                government can ensure proper destruction.
            (3) Report.--Not later than 12 months after the date of the 
        enactment of this Act, the Director of the Office of National 
        Drug Control Policy shall submit to Congress a report 
        containing the following:
                    (A) The findings of the study required under 
                paragraph (1).
                    (B) Any recommendations with respect to a 
                nationwide take-back program.
                    (C) The findings and recommendations submitted to 
                the Director by the Administrator of the Environmental 
                Protection Agency under subsection (b)(2).
    (b) Environmental Study.--
            (1) Study required.--The Administrator of the Environmental 
        Protection Agency shall conduct a study identifying the 
        environmental impacts of current prescription drug disposal 
        programs and methods.
            (2) Report.--Not later than 6 months after the date of the 
        enactment of this Act, the Administrator shall submit to the 
        Director of the Office of National Drug Control Policy a report 
        on the findings of the study conducted under paragraph (1), 
        with such recommendations as the Administrator considers 
        appropriate.
                                 <all>